Company Profile
CohBar Stock Price, News & Analysis
- Ticker:
- CWBR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for CWBR.
Company overview
Business overview
CohBar was a biotechnology company focused on mitochondria and aging biology before becoming a historical ticker. Its story reflected the challenge of turning aging-related science into a practical therapeutic thesis.
Geographic Base and Sector Classification
CohBar was headquartered in the United States and traded on NASDAQ. It sat in the platform-biotech and longevity research segment.
Business Model Characteristics
The business depended on preclinical validation, translational progress, and strategic funding. Investors historically watched whether the platform could move from concept to clinical relevance.
Position Within the Biotechnology Landscape
CohBar belongs in the historical longevity-biotech bucket. It was a science-heavy story where the market needed convincing evidence before assigning durable value.
Future catalysts
CohBar is a legacy / closeout story now, so the catalysts are any strategic or asset-resolution update rather than a live pipeline event. The market is mainly focused on what remains.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
CBIO · Source: Catalyst Biosciences
- 02
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
CBIO · Source: Catalyst Biosciences
- 03
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
CYCN · Source: Cyclerion
- 04
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
CBIO · Source: Catalyst Biosciences
- 05
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CBIO · Source: Catalyst Biosciences
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does CohBar do?
CohBar was a biotechnology company focused on mitochondria and aging biology before becoming a historical ticker. Its story reflected the challenge of turning aging-related science into a practical therapeutic thesis.
On which exchange is CWBR stock listed?
CohBar (CWBR) is associated with NASDAQ, United States, Biopharma.
What is CohBar?
CohBar is a legacy / closeout story now, so the catalysts are any strategic or asset-resolution update rather than a live pipeline event.
Which conditions is CohBar targeting with CohBar?
CohBar is a legacy / closeout story now, so the catalysts are any strategic or asset-resolution update rather than a live pipeline event.
How does CohBar describe recent progress with CohBar?
CohBar is a legacy / closeout story now, so the catalysts are any strategic or asset-resolution update rather than a live pipeline event.
What future catalysts are investors watching for CohBar?
CohBar is a legacy / closeout story now, so the catalysts are any strategic or asset-resolution update rather than a live pipeline event. The market is mainly focused on what remains.